Meplazumab, a humanized CD147 antibody that inhibits SARS-CoV-2 infection of host cells, has shown clinical benefits for COVID-19 patients.27 We then blocked infection of authentic SARS-CoV-2, BA.1 Omicron and BA.2 Omicron using meplazumab, which displayed that with the increase of concentration, inhibition rate of meplazumab gradually increased. The gene discussed is BSG; the disease is COVID-19.